Close Menu

More articles about Clinical Proteomics

With Medicare coverage for the test in place, the company is hoping it will surpass the limited commercial success of its initial Xpresys Lung offering.

A review by Max Planck researcher Matthias Mann and colleagues suggests that improved mass spec performance could enable more effective plasma marker discovery.

Johns Hopkins researchers added protein analysis to circulating tumor DNA testing to better detect early-stage pancreatic cancer.

The organization named the institutions that will be performing the proteomic and proteogenomic analyses planned to for the five-year, $65 million effort.

With the exception of Thermo Fisher Scientific, which released three new instruments, vendors focused mainly on expanded applications of existing platforms.

Progenetics will distribute GeneStrat and Veristrat liquid biopsy tests in Israel, making Biodesix's tests available in the Middle East for the first time.

The company plans to use the proceeds to support research collaborations and to expand its commercial team.

The two studies were part of larger project aimed at building a complete map of mitochondrial function and associated proteins. 

The results support a survival benefit for patients treated with therapies guided by combined DNA and mRNA sequencing and protein expression analyses. 

The assay is designed to measure changes in blood levels of the peptide precursor procalcitonin to differentiate bacterial infections from viral ones. 

Researchers also uncovered key pathways and alterations linked to differences in survival.

Along with scientists from the University of Leicester, the researchers picked the Xevo TQ-S micro platform to do a pilot study on heart failure patient samples.

The Swiss firm's assay combines a 29-gene host immune response panel with two tumor-derived proteins to detect early-stage colorectal cancer and large adenomatous polyps.

The company did not specify the number of shares it will offer or the offering price, but said it intends to trade on the Nasdaq Global Market.

The supply agreement was originally established between BG and the now defunct Health Diagnostics Laboratory, which was formerly BG's biggest customer.

Researchers from Protagen, Targos, and elsewhere have identified autoantibody biomarkers specific to patients diagnosed with prostate cancer.

The company said it plans to launch a clinical trial to validate its Immray PanCan-d blood test in both Europe and the US.

While much attention has focused on triple quads, MALDI-TOFs offer advantages in simplicity and throughput that could help them make clinical inroads.

The decision lets Vermillion access Medi-Cal's patient network, which covers more than 12.6 million lives, or roughly a third of California's covered lives.

In a large, prospective study published in Lancet Oncology, the screening assay was projected to reduce the number of prostate biopsies by 32 percent.

Pages

GenomeWeb reports that Veritas Genetics is suspending its US operations.

A Brazilian-led team of researchers reports it has generated a sugarcane genome assembly that encompasses more than 99 percent of its genome.

Certain plasma proteins could be used to gauge a person's age and whether they are aging well, according to HealthDay News.

In Science this week: approach to measure microRNA targeting efficiency, strategy to conduct high-throughput chemical screens at single-cell resolution, and more.